Introduction:

Hospital Acquired Disease Testing Market accounted for US$ 7.2 billion in 2020 and is estimated to be US$ 14.91 billion by 2030 and is anticipated to register a CAGR of 7.6%.

Hospital-acquired infections (HIA) are caused due to viral, bacterial, and fungal pathogens. Infection developed at a certain location such as hospitals due to presence of toxins is called as nosocomial infection or hospital acquired infections. Patients with compromised immune systems are at high risk of developing infection during their hospital stays. Infection can occur by several modes, which include healthcare staff, contaminated medical equipment, bed linens or air droplets. Also, infection can originate from the outside environment, another infected patient, staff that may be infected with unknown pathogen. Hospital acquired infections could be catheter-related bloodstream infection, surgical site infection, ventilator-associated pneumonia, and catheter-associated urinary tract infection.

Improper infection control practices and procedures at healthcare center and unclean and non-sterile environmental surfaces lead to development of hospital acquired diseases, which is driving growth of the hospital acquired disease testing market. Furthermore, increasing antibiotic resistance due to adoption of advanced medical care results into development of hospital acquired diseases, which in turn is fueling growth of the market. Moreover, increasing prevalence of nosocomial infections such as surgical wounds, urinary tract infections, and lower respiratory tract infections in intensive care units, orthopedic, and acute surgical ward are driving growth of the market.

Hospital acquired infection is a major burden for society, patients, and healthcare management. Increasing awareness among population regarding hospital acquired infections, adoption of infection control programs by healthcare facilities, maintaining personal hygiene by the hospital staff, complete sterilization of medical equipment, and a clean sanitary environment in the health care facilities may restrain growth of the hospital acquired disease testing market.

Hospital acquired disease testing market is segmented on the basis of test type and region. On the basis of test type, the market is segmented into urinary tract infection, surgical site infection, pneumonia, blood stream infection, methicillin-resistant staphylococcus aureus, and others.

Regional Insights:                                     

On the basis of region, the plant stem cells market finds its scope in North America, Europe, Latin America, Asia Pacific, Middle East and Africa. India hospital acquired infection diagnostics market is predicted to rise significantly due to rising occurrence of nosocomial illnesses such as surgical site infections and bloodstream infections. After completing a study on 10,835 patients in diverse clinical settings, India observed a 4.4 percent overall growth rate for hospital acquired illnesses, according to the Indian Journal of Basic and Applied Medical Research.

Report Scope:

Attribute	Details
Base year for estimation	2020
Forecast period	2020 – 2029
Market representation	Revenue in USD Million & CAGR from 2020 – 2029
Market Segmentation	By Test Type - Urinary Tract Infection, Surgical Site Infection, Pneumonia, Blood Stream Infection, Methicillin-resistant Staphylococcus Aureus, and others
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the

Hospital Acquired Disease Testing Market report based on Test Type and Region.

                                        

Hospital Acquired Disease Testing Market, By Region:

• North America

• U.S.
• Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating in the hospital acquired disease testing market include Diatherix laboratories, Life technologies, Cantel Medical Corporation Meridian Biosciences, Qiagen GmbH, Nordion, Roche, and Cepheid.

• Diatherix laboratories
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Life technologies
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Cantel Medical Corporation Meridian Biosciences
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Qiagen GmbH
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Nordion
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Roche
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Cepheid
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
3. Market Preview
   • Executive Summary
   • Key Findings—Global Outlook for medical carts Strategies
     • Key Questions this Study will Answer
     • Market Snippet, By Test Type
     • Market Snippet, By Region
   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restrains
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
5. Market Segmentation, By Test Type, Forecast Period up to 10 Years, (US$ Bn)
6. Overview
   • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
   • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
   • Segment Trends
7. Urinary Tract Infection
   • Overview
   • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
8. Surgical Site Infection
   • Overview
   • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
9. Pneumonia
   • Overview
   • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
10. Blood Stream Infection
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
11. Methicillin-resistant Staphylococcus Aureus
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
12. Global Market, By Region, Forecast Period up to 10 Years, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
      • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Bn), By Test Type, Forecast Period up to 10 Years
      • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Bn), By Test Type, Forecast Period up to 10 Years
      • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Bn), By Test Type, Forecast Period up to 10 Years
      • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
13. Latin America
    • Market Size and Forecast (US$ Bn), By Test Type, Forecast Period up to 10 Years
    • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
14. Brazil
15. Mexico
16. Rest of Latin America
17. Middle East & Africa
    • Market Size and Forecast (US$ Bn), By Test Type, Forecast Period up to 10 Years
    • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
18. GCC
19. Israel
20. South Africa
21. Rest of Middle East
22. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
23. Company Profiles
24. Diatherix laboratories
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
25. Life technologies
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
26. Cantel Medical Corporation Meridian Biosciences
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
27. Qiagen GmbH
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
28. Nordion
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
29. Roche
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
30. Cepheid
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
31. The Last Word
    • Future Impact
    • About Us
    • Contact